Every year in September, the pharmaceutical and medical industry turn all eyes on Munich. Then the awards “The Golden Pill” and “The Most Innovative Product”, also known as Pharma Oscars, are presented in the Deutsches Museum. This year, Surge-on Medical took second place in the “Startups” category.
Surge-on Medical’s CTO Tim Horeman was present at the gala on September 17th and received the award on behalf of the company. “Every day we are working to reduce instrument waste, improve surgeon’s performance and minimize total costs with our breakthrough innovations. The big smile on surgeons faces and often their unwillingness to return the instrument after a demonstration are some things that make me passionate about our technology. We are very pleased with the Pharma Trend “Most Innovative Product” Award 2019. It is a true recognition for the practical and technological innovativeness of our steerable, detachable and reusable minimally invasive instruments”, said Tim.
Since the year 2000 the most innovative and sustainable companies in the “Rx” category have been honored annually, and since 2018 in the categories “OTC”, “Orphan Drugs” and “Startups”, in 2019 the category “Specialty Care” has been added. The decision is based on the Pharma Trend survey, which is conducted among doctors, pharmacists and patients. In the “Startups” category, the winners are determined by a jury of 10 experts with many years of experience in biotechnology, medical technology, M&A and management, as well as in medicine and marketing of pharmaceuticals.
The event is under the patronage of the Bavarian State Ministry of Health and Care.
This award comes as the latest recognition of Surge-on Medical’s technology and market potential, as they are starring in the first European equity crowdfunding campaign, supported by EIT Health and aescuvest.eu. As Tim Horeman mentioned, “This award could be a great motivation for new investors in our currently running European equity crowdfunding campaign. Combining innovative excellence, with the right business fundamentals, and external recognition like this award, show that we are ready to disrupt the market of minimally invasive surgery!”